CN107532177A - 腺相关病毒变体及其使用方法 - Google Patents

腺相关病毒变体及其使用方法 Download PDF

Info

Publication number
CN107532177A
CN107532177A CN201680022686.1A CN201680022686A CN107532177A CN 107532177 A CN107532177 A CN 107532177A CN 201680022686 A CN201680022686 A CN 201680022686A CN 107532177 A CN107532177 A CN 107532177A
Authority
CN
China
Prior art keywords
gly
pro
asn
leu
ala
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680022686.1A
Other languages
English (en)
Chinese (zh)
Inventor
D·S·欧加拉
J·桑蒂阿格-欧蒂兹
O·韦斯特桑
D·V·沙弗尔
I·H·霍尔米斯
J·温斯特恩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California San Diego UCSD
Original Assignee
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California San Diego UCSD filed Critical University of California San Diego UCSD
Publication of CN107532177A publication Critical patent/CN107532177A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/864—Parvoviral vectors, e.g. parvovirus, densovirus
    • C12N15/8645—Adeno-associated virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201680022686.1A 2015-03-24 2016-03-23 腺相关病毒变体及其使用方法 Pending CN107532177A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562137580P 2015-03-24 2015-03-24
US62/137,580 2015-03-24
PCT/US2016/023822 WO2016154344A1 (en) 2015-03-24 2016-03-23 Adeno-associated virus variants and methods of use thereof

Publications (1)

Publication Number Publication Date
CN107532177A true CN107532177A (zh) 2018-01-02

Family

ID=56978687

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680022686.1A Pending CN107532177A (zh) 2015-03-24 2016-03-23 腺相关病毒变体及其使用方法

Country Status (9)

Country Link
US (2) US10883117B2 (enExample)
EP (1) EP3277819B1 (enExample)
JP (1) JP6836999B2 (enExample)
CN (1) CN107532177A (enExample)
AU (1) AU2016235163B2 (enExample)
CA (1) CA2979065A1 (enExample)
ES (1) ES2860712T3 (enExample)
MX (1) MX388331B (enExample)
WO (1) WO2016154344A1 (enExample)

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110295151A (zh) * 2019-07-17 2019-10-01 博鑫仪器(天津)有限公司 一类腺依赖病毒病毒重组质粒、重组病毒及构建方法
CN110950934A (zh) * 2019-12-31 2020-04-03 复旦大学 一种腺相关病毒衣壳蛋白、载体及其构建方法与应用
CN111909246A (zh) * 2019-05-08 2020-11-10 中国科学院脑科学与智能技术卓越创新中心 高效感染支持细胞的aav突变体
CN112041442A (zh) * 2018-02-28 2020-12-04 北卡罗来纳大学查佩尔希尔分校 用于逃避抗体的病毒载体的方法和组合物
CN112226461A (zh) * 2020-08-21 2021-01-15 华侨大学 Cd4阳性细胞特异性基因传递载体及其应用
CN112424217A (zh) * 2018-05-14 2021-02-26 生物马林药物股份有限公司 肝脏靶向的腺病毒相关病毒载体
CN112566923A (zh) * 2018-06-12 2021-03-26 北卡罗来纳大学教堂山分校 合成嗜肝性腺相关病毒衣壳及其用途
WO2021073568A1 (en) * 2019-10-16 2021-04-22 Wuxi Apptec (Shanghai) Co., Ltd. A novel aav variant
CN113121654A (zh) * 2021-04-19 2021-07-16 信念医药科技(上海)有限公司 新型腺相关病毒衣壳蛋白及包含其的新型腺相关病毒载体
CN113121653A (zh) * 2021-04-19 2021-07-16 上海信致医药科技有限公司 肌肉和视网膜特异性的新型腺相关病毒衣壳蛋白
CN113717248A (zh) * 2020-09-30 2021-11-30 广州派真生物技术有限公司 腺相关病毒突变体及其应用
CN114502575A (zh) * 2019-06-10 2022-05-13 同源药物公司 用于arsa基因转移的腺相关病毒组合物和其使用方法
CN114729384A (zh) * 2019-09-12 2022-07-08 博德研究所 工程化腺相关病毒衣壳
CN115087738A (zh) * 2019-08-29 2022-09-20 小利兰·斯坦福大学托管委员会 用于穿越人血脑屏障的腺相关病毒载体
CN115551878A (zh) * 2020-05-01 2022-12-30 波士顿学院董事会 用于增强的基因疗法的腺相关病毒(aav)的受控修饰
WO2023108507A1 (en) * 2021-12-15 2023-06-22 National Institute Of Biological Sciences, Beijing Recombinant aav vectors and use thereof
EP4244360A4 (en) * 2020-11-16 2025-05-07 Beijing SoloBio Genetechnology Company Ltd. Recombinant adeno-associated viruses with enhanced liver tropism and uses thereof
US12410447B2 (en) 2019-10-16 2025-09-09 The Broad Institute, Inc. Engineered muscle targeting compositions

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160369298A1 (en) 2013-09-26 2016-12-22 University Of Florida Research Foundation, Inc. Synthetic combinatorial aav capsid library for targeted gene therapy
JP6689249B2 (ja) 2014-03-17 2020-05-20 アドヴェラム バイオテクノロジーズ， インコーポレイテッド 錐体細胞における増強された遺伝子発現のための組成物および方法
WO2015191508A1 (en) 2014-06-09 2015-12-17 Voyager Therapeutics, Inc. Chimeric capsids
RU2716991C2 (ru) 2014-11-05 2020-03-17 Вояджер Терапьютикс, Инк. Полинуклеотиды aadc для лечения болезни паркинсона
RU2716422C2 (ru) 2014-11-14 2020-03-11 Вояджер Терапьютикс, Инк. Композиции и способы лечения бокового амиотрофического склероза (als)
CN112410339A (zh) 2014-11-14 2021-02-26 沃雅戈治疗公司 调节性多核苷酸
HK1245326A1 (zh) 2014-12-12 2018-08-24 Voyager Therapeutics, Inc. 用於生产scaav的组合物和方法
GB201508026D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Capsid
GB201508025D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Fabry disease gene therapy
CN108137655B (zh) 2015-09-28 2022-04-22 北卡罗来纳-查佩尔山大学 逃避抗体的病毒载体的方法和组合物
US12188037B2 (en) 2015-10-22 2025-01-07 University Of Florida Research Foundation, Incorporated Synthetic combinatorial AAV3 capsid library
US10983110B2 (en) 2015-12-02 2021-04-20 Voyager Therapeutics, Inc. Assays for the detection of AAV neutralizing antibodies
WO2017189959A1 (en) 2016-04-29 2017-11-02 Voyager Therapeutics, Inc. Compositions for the treatment of disease
WO2017189964A2 (en) 2016-04-29 2017-11-02 Voyager Therapeutics, Inc. Compositions for the treatment of disease
CA3252099A1 (en) 2016-05-18 2025-06-05 Voyager Therapeutics, Inc. MODULATING POLYNUCLEOTIDES
CN109831916B (zh) 2016-05-18 2023-07-21 沃雅戈治疗公司 治疗亨廷顿氏舞蹈病的组合物和方法
KR20230039779A (ko) 2016-07-29 2023-03-21 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 변이체 캡시드를 갖는 아데노-관련된 바이러스 비리온 및 이의 사용 방법
EP3506817A4 (en) 2016-08-30 2020-07-22 The Regents of The University of California Methods for biomedical targeting and delivery and devices and systems for practicing the same
CA3040179A1 (en) 2016-10-19 2018-04-26 Adverum Biotechnologies, Inc. Modified aav capsids and uses thereof
EP3585883A4 (en) 2017-02-21 2021-04-14 University of Florida Research Foundation, Incorporated MODIFIED AAV CAPSID PROTEINS AND USES THEREOF
JP2020518258A (ja) 2017-05-05 2020-06-25 ボイジャー セラピューティクス インコーポレイテッドＶｏｙａｇｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 筋萎縮性側索硬化症（ａｌｓ）治療組成物および方法
JP2020518259A (ja) 2017-05-05 2020-06-25 ボイジャー セラピューティクス インコーポレイテッドＶｏｙａｇｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． ハンチントン病治療組成物および方法
WO2018211409A1 (en) 2017-05-15 2018-11-22 University Of Florida Research Foundation, Inc. Core master regulators of glioblastoma stem cells
JOP20190269A1 (ar) 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون
WO2019006182A1 (en) 2017-06-30 2019-01-03 The Regents Of The University Of California VIRIONS OF ADENO-ASSOCIATED VIRUSES OF CAPSID VARIANTS AND METHODS OF USE THEREOF
WO2019018342A1 (en) 2017-07-17 2019-01-24 Voyager Therapeutics, Inc. NETWORK EQUIPMENT TRACK GUIDE SYSTEM
KR102850887B1 (ko) 2017-08-03 2025-08-28 보이저 테라퓨틱스, 인크. Aav의 전달을 위한 조성물 및 방법
NZ763018A (en) * 2017-09-20 2023-02-24 4D Molecular Therapeutics Inc Adeno-associated virus variant capsids and methods of use thereof
MX2020003042A (es) 2017-09-29 2020-11-18 Voyager Therapeutics Inc Rescate del fenotipo neurológico central y periférico de la ataxia de friedreich mediante administración intravenosa.
CN119242711A (zh) 2017-10-16 2025-01-03 沃雅戈治疗公司 肌萎缩性侧索硬化症（als）的治疗
US20200237799A1 (en) 2017-10-16 2020-07-30 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis (als)
SG11202009451VA (en) 2018-04-03 2020-10-29 Stridebio Inc Antibody-evading virus vectors
CA3094465A1 (en) 2018-04-03 2019-10-10 Stridebio, Inc. Virus vectors for targeting ophthalmic tissues
JP7406677B2 (ja) 2018-04-03 2023-12-28 ギンコ バイオワークス インコーポレイテッド 抗体を回避するウイルスベクター
BR112020023082A2 (pt) 2018-05-15 2021-02-09 Voyager Therapeutics, Inc. composições e métodos para o tratamento de doença de parkinson
CA3111076A1 (en) 2018-08-30 2020-03-05 Tenaya Therapeutics, Inc. Cardiac cell reprogramming with myocardin and ascl1
CN113966399A (zh) 2018-09-26 2022-01-21 加州理工学院 用于靶向基因疗法的腺相关病毒组合物
CA3114621A1 (en) 2018-09-28 2020-04-02 Voyager Therapeutics, Inc. Frataxin expression constructs having engineered promoters and methods of use thereof
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
CA3133453A1 (en) 2019-03-21 2020-09-24 Daniel Mccoy Recombinant adeno-associated virus vectors
US20220154217A1 (en) 2019-04-01 2022-05-19 Tenaya Therapeutics, Inc. Adeno-associated virus with engineered capsid
US20230137971A1 (en) 2019-07-11 2023-05-04 Tenaya Therapeutics Inc. Cardiac cell reprogramming with micrornas and other factors
JP2022544237A (ja) * 2019-08-09 2022-10-17 ユニバーシティー オブ フロリダ リサーチ ファンデーション， インク． ヒト神経膠芽腫細胞をターゲティングするためのａａｖカプシドバリアント
TW202128736A (zh) 2019-10-17 2021-08-01 美商史崔德生物公司 用於治療ｃ型尼曼—匹克病之腺相關病毒載體
KR20220139956A (ko) 2020-02-13 2022-10-17 테나야 테라퓨틱스, 인코포레이티드 심장 질환을 치료하기 위한 유전자 요법 벡터
WO2021163357A2 (en) 2020-02-13 2021-08-19 Tenaya Therapeutics, Inc. Gene therapy vectors for treating heart disease
KR20220149590A (ko) 2020-03-02 2022-11-08 테나야 테라퓨틱스, 인코포레이티드 심근세포-발현 마이크로rna에 의한 유전자 벡터 제어
IL297404A (en) 2020-04-27 2022-12-01 4D Molecular Therapeutics Inc Codon-optimized gla genes and their uses
CN111560399B (zh) * 2020-05-22 2021-07-06 苏州君盟生物医药科技有限公司 细胞大规模瞬时转染方法
KR20230043794A (ko) 2020-05-29 2023-03-31 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 변이체 캡시드를 갖는 아데노-연관 바이러스 비리온 및 이의 사용 방법
WO2022011390A1 (en) * 2020-07-08 2022-01-13 Baylor College Of Medicine Gene therapy for stxbp1 encephalopathy
CN116745409A (zh) 2020-08-19 2023-09-12 萨雷普塔治疗公司 用于治疗雷特综合征的腺相关病毒载体
CN112080521B (zh) * 2020-09-07 2022-05-31 山东农业大学 一种表达外源蛋白的重组伪狂犬病毒载体构建及重组伪狂犬病毒制备方法
US11781156B2 (en) 2020-10-09 2023-10-10 Tenaya Therapeutics, Inc. Plakophillin-2 gene therapy methods and compositions
WO2022087104A1 (en) * 2020-10-21 2022-04-28 Chan Zuckerberg Biohub, Inc. Adeno-associated virus virions and methods of use thereof
US12285444B2 (en) * 2020-12-08 2025-04-29 Duke University Multicistronic miRNA delivery for cardiac reprogramming
CN118510905A (zh) * 2021-12-06 2024-08-16 学校法人顺天堂 改变型腺伴随病毒载体
TW202421787A (zh) 2022-09-06 2024-06-01 美商特納亞治療股份有限公司 保護心臟之心臟病療法
CN117304256B (zh) * 2022-12-08 2024-04-16 广州派真生物技术有限公司 腺相关病毒突变体及其应用
WO2024215655A1 (en) 2023-04-10 2024-10-17 Tenaya Therapeutics, Inc. Cardioprotective bag3 therapies
WO2024215653A1 (en) 2023-04-10 2024-10-17 Tenaya Therapeutics, Inc. Guide rnas, vectors, and virions for targeting mutations in the pln gene
AU2024271436A1 (en) * 2023-05-15 2025-11-13 Sangamo Therapeutics, Inc. Engineered blood brain barrier penetrant aav capsids

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005005610A2 (en) * 2003-06-30 2005-01-20 The Regents Of The University Of California Mutant adeno-associated virus virions and methods of use thereof
CN103561774A (zh) * 2011-04-22 2014-02-05 加利福尼亚大学董事会 具有变异衣壳的腺相关病毒病毒体及其使用方法
CN106232618A (zh) * 2013-10-11 2016-12-14 马萨诸塞眼科耳科诊所 预测祖先病毒序列的方法及其用途

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
WO1992001070A1 (en) 1990-07-09 1992-01-23 The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce High efficiency packaging of mutant adeno-associated virus using amber suppressions
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
CA2115742A1 (en) 1991-08-20 1993-03-04 Ronald G. Crystal Adenovirus mediated transfer of genes to the gastrointestinal tract
GB9206016D0 (en) 1992-03-19 1992-04-29 Sandoz Ltd Improvements in or relating to organic compounds
WO1995005864A1 (en) 1993-08-27 1995-03-02 Government Of The United States Of America, Represented By The Secretary Of The Department Of Health And Human Services Convection-enhanced drug delivery
US6440425B1 (en) 1995-05-01 2002-08-27 Aventis Pasteur Limited High molecular weight major outer membrane protein of moraxella
US6093570A (en) 1995-06-07 2000-07-25 The University Of North Carolina At Chapel Hill Helper virus-free AAV production
US6001650A (en) 1995-08-03 1999-12-14 Avigen, Inc. High-efficiency wild-type-free AAV helper functions
US6096548A (en) 1996-03-25 2000-08-01 Maxygen, Inc. Method for directing evolution of a virus
WO1997038723A1 (en) 1996-04-16 1997-10-23 Immusol Incorporated Targeted viral vectors
US6710036B2 (en) 1997-07-25 2004-03-23 Avigen, Inc. Induction of immune response to antigens expressed by recombinant adeno-associated virus
WO1999014354A1 (en) 1997-09-19 1999-03-25 The Trustees Of The University Of The Pennsylvania Methods and vector constructs useful for production of recombinant aav
AU1449499A (en) 1997-10-31 1999-05-24 Maxygen, Incorporated Modification of virus tropism and host range by viral genome shuffling
US6410300B1 (en) 1998-01-12 2002-06-25 The University Of North Carolina At Chapel Hill Methods and formulations for mediating adeno-associated virus (AAV) attachment and infection and methods for purifying AAV
US6551795B1 (en) 1998-02-18 2003-04-22 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to pseudomonas aeruginosa for diagnostics and therapeutics
DE19827457C1 (de) 1998-06-19 2000-03-02 Medigene Ag Strukturprotein von AAV, seine Herstellung und Verwendung
ATE294874T1 (de) 1998-09-11 2005-05-15 Univ California Rekombinante adenovirus für gewebespezifische genexpression ins herz
DE69941905D1 (de) 1998-11-10 2010-02-25 Univ North Carolina Virusvektoren und verfahren für ihre herstellung und verabreichung.
US6943153B1 (en) 1999-03-15 2005-09-13 The Regents Of The University Of California Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
US6498244B1 (en) 1999-05-28 2002-12-24 Cell Genesys, Inc. Adeno-associated virus capsid immunologic determinants
US7314912B1 (en) 1999-06-21 2008-01-01 Medigene Aktiengesellschaft AAv scleroprotein, production and use thereof
DE19933288A1 (de) 1999-07-15 2001-01-18 Medigene Ag Strukturprotein von Adeno-assoziiertem Virus mit veränderter Antigenität, seine Herstellung und Verwendung
DE19933719A1 (de) 1999-07-19 2001-01-25 Medigene Ag Strukturprotein in Adeno-assoziiertem Virus mit veränderten chromatographischen Eigenschaften, seine Herstellung und Verwendung
US8232081B2 (en) 1999-09-21 2012-07-31 Basf Se Methods and microorganisms for production of panto-compounds
US6855314B1 (en) 2000-03-22 2005-02-15 The United States Of America As Represented By The Department Of Health And Human Services AAV5 vector for transducing brain cells and lung cells
IL140110A0 (en) 2000-12-05 2002-02-10 Applied Research Systems Improvement of homogeneity and secretion of recombinant proteins in mammalian systems
AU2002248297A1 (en) 2001-01-05 2002-07-16 Children's Hospital, Inc. Aav2 vectors and methods
US7749492B2 (en) 2001-01-05 2010-07-06 Nationwide Children's Hospital, Inc. AAV vectors and methods
EP1386004A4 (en) 2001-04-05 2005-02-16 Ribozyme Pharm Inc MODULATION OF GENE EXPRESSION ASSOCIATED WITH INFLAMMATORY PROLIFERATION AND GROWTH OF NEURITIES BY METHODS INVOLVING NUCLEIC ACID
US20030129203A1 (en) 2001-08-27 2003-07-10 Nautilus Biotech S.A. Mutant recombinant adeno-associated viruses
US7647184B2 (en) 2001-08-27 2010-01-12 Hanall Pharmaceuticals, Co. Ltd High throughput directed evolution by rational mutagenesis
EP1572893B1 (en) 2001-11-09 2009-01-07 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY of the DEPARTMENT OF HEALTH AND HUMAN SERVICES Production of adeno-associated virus in insect cells
NZ618298A (en) 2001-11-13 2015-04-24 Univ Pennsylvania A method of detecting and/or identifying adeno-associated virus (aav) sequences and isolating novel sequences identified thereby
US20050106558A1 (en) 2001-12-21 2005-05-19 Luca Perabo Library of modified structural genes or capsid modified particles useful for the identification of viral clones with desired cell tropism
US20060292117A1 (en) 2002-04-17 2006-12-28 Loiler Scott A Improved rAAv vectors
WO2003092594A2 (en) 2002-04-30 2003-11-13 Duke University Adeno-associated viral vectors and methods for their production from hybrid adenovirus and for their use
AU2003237159A1 (en) 2002-04-30 2003-11-17 University Of Florida Treatment for phenylketonuria
US7254489B2 (en) * 2002-05-31 2007-08-07 Microsoft Corporation Systems, methods and apparatus for reconstructing phylogentic trees
AU2003265855A1 (en) 2002-08-28 2004-03-19 University Of Florida Modified aav
WO2004083441A2 (en) 2003-03-19 2004-09-30 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Random peptide library displayed on aav vectors
WO2004108922A2 (en) 2003-04-25 2004-12-16 The Trustees Of The University Of Pennsylvania Use of aav comprising a capsid protein from aav7 or aav8 for the delivery of genes encoding apoprotein a or e genes to the liver
EP1486567A1 (en) 2003-06-11 2004-12-15 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Improved adeno-associated virus (AAV) vector for gene therapy
PT2657248T (pt) 2003-06-19 2017-06-26 Genzyme Corp Viriões aav com imunorreatividade diminuída e seus usos
WO2005000240A2 (en) 2003-06-23 2005-01-06 A & G Pharmaceutical, Inc. Compositions and methods for restoring sensitivity of tumor cells to antitumor therapy and inducing apoptosis
GB0314856D0 (en) 2003-06-25 2003-07-30 Unitargeting Res As Protein expression system
US9233131B2 (en) 2003-06-30 2016-01-12 The Regents Of The University Of California Mutant adeno-associated virus virions and methods of use thereof
US8106180B2 (en) 2003-08-07 2012-01-31 Whitehead Institute For Biomedical Research Methods and products for expression of micro RNAs
US20050142581A1 (en) 2003-09-04 2005-06-30 Griffey Richard H. Microrna as ligands and target molecules
WO2005030932A2 (en) 2003-09-24 2005-04-07 The Board Of Trustees Of The Leland Stanford Junior University Igf-1 instructs multipotent adult cns neural stem cells to an oligodendroglial lineage
EP2292780B1 (en) 2003-09-30 2017-08-23 The Trustees Of The University Of Pennsylvania Adeno-associated virus (AAV) clades, sequences, vectors containing same, and uses thereof
US20050266552A1 (en) 2003-12-05 2005-12-01 Doench John G Reagents and methods for identification of RNAi pathway genes and chemical modulators of RNAi
KR100614827B1 (ko) 2004-05-06 2006-08-25 재단법인서울대학교산학협력재단 양방향 은닉 마코프 모델을 이용한 완숙한마이크로알엔에이 위치예측방법 및 이를 구현하기 위한컴퓨터 프로그램을 기록한 저장매체
US7427396B2 (en) 2004-06-03 2008-09-23 Genzyme Corporation AAV vectors for gene delivery to the lung
EP1828390B1 (en) 2004-12-15 2012-06-13 The University Of North Carolina At Chapel Hill Chimeric vectors
WO2006101634A1 (en) 2005-02-17 2006-09-28 The Regents Of The University Of California Müller cell specific gene therapy
EP2359865B1 (en) 2005-04-07 2013-10-02 The Trustees of The University of Pennsylvania Method of increasing the function of an AAV vector
WO2006128063A2 (en) 2005-05-25 2006-11-30 Irm Llc Methods and compositions for inhibiting glioma growth
US8119766B2 (en) 2005-06-02 2012-02-21 University Of Iowa Research Foundation Increasing functional glycosylation of alpha-dystroglycan in the treatment of muscle degeneration
WO2007089632A2 (en) 2006-01-27 2007-08-09 The University Of North Carolina At Chapel Hill Heparin and heparan sulfate binding chimeric vectors
EP2007795B1 (en) 2006-03-30 2016-11-16 The Board Of Trustees Of The Leland Stanford Junior University Aav capsid proteins
PT2019683T (pt) 2006-04-25 2017-03-17 Univ California Administração de fatores de crescimento para o tratamento de distúrbios do snc
EP2019588A4 (en) 2006-05-04 2010-11-24 Univ Wayne State RESTORATION OF VISUAL RESPONSES BY IN VIVO ADMINISTRATION OF NUCLEIC ACIDS OF RHODOPSIN
DK2061891T3 (da) 2006-08-24 2012-07-23 Virovek Inc Ekspression i insektceller af gener med overlappende åbne læserammer, fremgangsmåder og sammensætninger hertil
CN1966082B (zh) 2006-11-03 2010-06-30 许瑞安 一种防治结直肠癌的基因药物及其制备方法和用途
US9725485B2 (en) * 2012-05-15 2017-08-08 University Of Florida Research Foundation, Inc. AAV vectors with high transduction efficiency and uses thereof for gene therapy
NZ579985A (en) 2007-04-13 2012-02-24 Catalyst Biosciences Inc Modified factor vii polypetides and uses thereof
EP1985708B1 (en) 2007-04-27 2015-04-15 Universität Rostock Selective targeting of viruses to neural precursor cells
US7951785B2 (en) 2007-09-21 2011-05-31 California Institute Of Technology NFIA in glial fate determination, glioma therapy and astrocytoma treatment
US8632764B2 (en) 2008-04-30 2014-01-21 University Of North Carolina At Chapel Hill Directed evolution and in vivo panning of virus vectors
US20120093772A1 (en) 2008-05-20 2012-04-19 Alan Horsager Vectors for delivery of light sensitive proteins and methods of use
US8541568B2 (en) 2008-05-24 2013-09-24 Hai Yan Compositions and methods using siRNA molecules for treatment of gliomas
EP2297185A1 (en) 2008-06-17 2011-03-23 Amsterdam Molecular Therapeutics (AMT) B.V. Parvoviral capsid with incorporated gly-ala repeat region
EP2396343B1 (en) 2009-02-11 2017-05-17 The University of North Carolina At Chapel Hill Modified virus vectors and methods of making and using the same
CN101532024A (zh) 2009-04-30 2009-09-16 许瑞安 一种用于基因治疗的新型细胞特异性内含microRNA结合序列的基因HAAVmir
WO2010138263A2 (en) 2009-05-28 2010-12-02 University Of Massachusetts Novel aav 's and uses thereof
US20110059114A1 (en) 2009-08-05 2011-03-10 Duke University Compositions and Methods for the Treatment of Radioresistant Glioma Stem Cells
WO2011117258A2 (en) 2010-03-22 2011-09-29 Association Institut De Myologie Methods of increasing efficiency of vector penetration of target tissue
WO2011134023A1 (en) 2010-04-30 2011-11-03 The University Of Queensland Inhibition of glioma
US8663624B2 (en) 2010-10-06 2014-03-04 The Regents Of The University Of California Adeno-associated virus virions with variant capsid and methods of use thereof
WO2013029030A1 (en) 2011-08-24 2013-02-28 The Board Of Trustees Of The Leland Stanford Junior University New aav capsid proteins for nucleic acid transfer
US9260755B2 (en) 2012-04-11 2016-02-16 University Of Massachusetts Compositions and methods for characterizing and treating muscular dystrophy
JP6385920B2 (ja) 2012-05-09 2018-09-05 オレゴン ヘルス アンド サイエンス ユニバーシティー アデノ随伴ウイルスプラスミド及びベクター
TWI702955B (zh) 2012-05-15 2020-09-01 澳大利亞商艾佛蘭屈澳洲私營有限公司 使用腺相關病毒（ａａｖ）ｓｆｌｔ-１治療老年性黃斑部退化（ａｍｄ）
RS59199B1 (sr) 2012-05-25 2019-10-31 Univ California Metode i jedinjenja za rnk-upravljanu ciljanu dnk modifikaciju i za rnk- upravljanu modulaciju transkripta
JP6363958B2 (ja) 2012-12-25 2018-07-25 タカラバイオ株式会社 Ａａｖ変異体
US11685935B2 (en) 2013-05-29 2023-06-27 Cellectis Compact scaffold of Cas9 in the type II CRISPR system
ES2897508T3 (es) 2013-05-31 2022-03-01 Univ California Variantes de virus adenoasociados y métodos de uso de las mismas
US20160369298A1 (en) 2013-09-26 2016-12-22 University Of Florida Research Foundation, Inc. Synthetic combinatorial aav capsid library for targeted gene therapy
PE20170260A1 (es) 2014-05-02 2017-04-12 Genzyme Corp Vectores de aav para la terapia genica de la retina y el snc
WO2015191693A2 (en) 2014-06-10 2015-12-17 Massachusetts Institute Of Technology Method for gene editing
AU2016226289B2 (en) 2015-03-02 2021-04-29 Adverum Biotechnologies, Inc. Compositions and methods for intravitreal delivery of polynucleotides to retinal cones
HUE051491T2 (hu) * 2015-03-06 2021-03-01 Massachusetts Eye & Ear Infirmary Gén-augmentációs terápiák a PRPF31 gén mutációi által okozott öröklött retina degenerációra
US20190000940A1 (en) 2015-07-31 2019-01-03 Voyager Therapeutics, Inc. Compositions and methods for the treatment of aadc deficiency
DK4206216T3 (da) * 2016-05-13 2025-12-01 4D Molecular Therapeutics Inc Adeno-associerede virusvarianter og fremgangsmåder til brug deraf

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005005610A2 (en) * 2003-06-30 2005-01-20 The Regents Of The University Of California Mutant adeno-associated virus virions and methods of use thereof
CN103561774A (zh) * 2011-04-22 2014-02-05 加利福尼亚大学董事会 具有变异衣壳的腺相关病毒病毒体及其使用方法
CN106232618A (zh) * 2013-10-11 2016-12-14 马萨诸塞眼科耳科诊所 预测祖先病毒序列的方法及其用途

Cited By (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112041442A (zh) * 2018-02-28 2020-12-04 北卡罗来纳大学查佩尔希尔分校 用于逃避抗体的病毒载体的方法和组合物
CN112424217A (zh) * 2018-05-14 2021-02-26 生物马林药物股份有限公司 肝脏靶向的腺病毒相关病毒载体
CN112566923A (zh) * 2018-06-12 2021-03-26 北卡罗来纳大学教堂山分校 合成嗜肝性腺相关病毒衣壳及其用途
CN111909246A (zh) * 2019-05-08 2020-11-10 中国科学院脑科学与智能技术卓越创新中心 高效感染支持细胞的aav突变体
CN111909246B (zh) * 2019-05-08 2024-01-19 中国科学院脑科学与智能技术卓越创新中心 高效感染支持细胞的aav突变体
CN114502575A (zh) * 2019-06-10 2022-05-13 同源药物公司 用于arsa基因转移的腺相关病毒组合物和其使用方法
CN110295151A (zh) * 2019-07-17 2019-10-01 博鑫仪器(天津)有限公司 一类腺依赖病毒病毒重组质粒、重组病毒及构建方法
CN115087738A (zh) * 2019-08-29 2022-09-20 小利兰·斯坦福大学托管委员会 用于穿越人血脑屏障的腺相关病毒载体
CN114729384A (zh) * 2019-09-12 2022-07-08 博德研究所 工程化腺相关病毒衣壳
US12410447B2 (en) 2019-10-16 2025-09-09 The Broad Institute, Inc. Engineered muscle targeting compositions
WO2021073568A1 (en) * 2019-10-16 2021-04-22 Wuxi Apptec (Shanghai) Co., Ltd. A novel aav variant
CN113518824B (zh) * 2019-10-16 2024-02-23 上海药明康德新药开发有限公司 新的aav变体
CN113518824A (zh) * 2019-10-16 2021-10-19 上海药明康德新药开发有限公司 新的aav变体
CN110950934A (zh) * 2019-12-31 2020-04-03 复旦大学 一种腺相关病毒衣壳蛋白、载体及其构建方法与应用
CN110950934B (zh) * 2019-12-31 2022-11-04 复旦大学 一种腺相关病毒衣壳蛋白、载体及其构建方法与应用
CN115551878A (zh) * 2020-05-01 2022-12-30 波士顿学院董事会 用于增强的基因疗法的腺相关病毒(aav)的受控修饰
CN112226461B (zh) * 2020-08-21 2022-04-22 华侨大学 Cd4阳性细胞特异性基因传递载体及其应用
CN112226461A (zh) * 2020-08-21 2021-01-15 华侨大学 Cd4阳性细胞特异性基因传递载体及其应用
CN113754727A (zh) * 2020-09-30 2021-12-07 广州派真生物技术有限公司 腺相关病毒突变体及其应用
CN113717248A (zh) * 2020-09-30 2021-11-30 广州派真生物技术有限公司 腺相关病毒突变体及其应用
EP4244360A4 (en) * 2020-11-16 2025-05-07 Beijing SoloBio Genetechnology Company Ltd. Recombinant adeno-associated viruses with enhanced liver tropism and uses thereof
CN113121654B (zh) * 2021-04-19 2023-11-17 信念医药科技(上海)有限公司 腺相关病毒衣壳蛋白及包含其的腺相关病毒载体
CN113121653A (zh) * 2021-04-19 2021-07-16 上海信致医药科技有限公司 肌肉和视网膜特异性的新型腺相关病毒衣壳蛋白
CN113121654A (zh) * 2021-04-19 2021-07-16 信念医药科技(上海)有限公司 新型腺相关病毒衣壳蛋白及包含其的新型腺相关病毒载体
WO2023108507A1 (en) * 2021-12-15 2023-06-22 National Institute Of Biological Sciences, Beijing Recombinant aav vectors and use thereof

Also Published As

Publication number Publication date
US20180066285A1 (en) 2018-03-08
EP3277819A1 (en) 2018-02-07
WO2016154344A1 (en) 2016-09-29
ES2860712T3 (es) 2021-10-05
JP2018514190A (ja) 2018-06-07
HK1246355A1 (zh) 2018-09-07
EP3277819A4 (en) 2018-09-05
CA2979065A1 (en) 2016-09-29
AU2016235163B2 (en) 2022-03-24
EP3277819B1 (en) 2021-03-03
AU2016235163A1 (en) 2017-10-05
MX388331B (es) 2025-03-19
MX2017012097A (es) 2018-06-15
US10883117B2 (en) 2021-01-05
US20210147876A1 (en) 2021-05-20
JP6836999B2 (ja) 2021-03-03

Similar Documents

Publication Publication Date Title
EP3277819B1 (en) Adeno-associated virus variants and methods of use thereof
US12221616B2 (en) Adeno-associated virus variant capsids and methods of use thereof
US11680249B2 (en) Adeno-associated virus capsid variants and methods of use thereof
ES2714292T3 (es) Composiciones de vector raav3 con cápside modificada y métodos de uso en terapia génica del cáncer de hígado humano
CN113727992A (zh) 重组腺相关病毒载体
AU2014274457A1 (en) Capsid-modified, rAAV3 vector compositions and uses in gene therapy of human liver cancer
AU2021265768B2 (en) Adeno-associated variants, formulations and methods for pulmonary delivery
CA3185281A1 (en) Compositions useful for treatment of charcot-marie-tooth disease
BR112021001498A2 (pt) vírus adeno-associado recombinante (raav), composição farmacêutica, polinucleotídeo, plasmídeo de raav, célula ex vivo, método de produção de um raav e métodos para tratar um sujeito humano diagnosticado com mucopolissacaridose tipo iva (mps iva)
CN111718420A (zh) 一种用于基因治疗的融合蛋白及其应用
CN118401667A (zh) 用于治疗cdkl5缺乏症(cdd)的组合物
CN108103102A (zh) 一种aav1病毒介导的骨骼肌特异性pck1基因表达载体及其用途
HK1246355B (en) Adeno-associated virus variants and methods of use thereof
US20250163469A1 (en) Adeno-associated virus variant capsids and methods of use thereof
KR20240154633A (ko) 개선된 폐 향성을 갖는 아데노-관련 바이러스 변이체 캡시드 및 이의 용도
HK40036161A (en) Adeno-associated virus variant capsids and methods of use thereof
Ojala Improved Strategies for Directed Evolution of Adeno-Associated Virus Gene Therapy Vectors
WO2020187272A1 (zh) 一种用于基因治疗的融合蛋白及其应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
AD01 Patent right deemed abandoned

Effective date of abandoning: 20220920

AD01 Patent right deemed abandoned